These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 29693178)

  • 1. Identifying genes as potential prognostic indicators in patients with serous ovarian cancer resistant to carboplatin using integrated bioinformatics analysis.
    Zhan SJ; Liu B; Linghu H
    Oncol Rep; 2018 Jun; 39(6):2653-2663. PubMed ID: 29693178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross‑validation of genes potentially associated with neoadjuvant chemotherapy and platinum‑based chemoresistance in epithelial ovarian carcinoma.
    Zhang K; Wang W; Chen L; Liu Y; Hu J; Guo F; Tian W; Wang Y; Xue F
    Oncol Rep; 2020 Sep; 44(3):909-926. PubMed ID: 32705213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of Hub Genes in High-Grade Serous Ovarian Cancer Using Weighted Gene Co-Expression Network Analysis.
    Wu M; Sun Y; Wu J; Liu G
    Med Sci Monit; 2020 Mar; 26():e922107. PubMed ID: 32180586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploration of the sequential gene changes in epithelial ovarian cancer induced by carboplatin via microarray analysis.
    Wei S; Liu J; Shi Y; Zhang X; Yang Y; Song Q
    Mol Med Rep; 2017 Sep; 16(3):3155-3160. PubMed ID: 28713952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of Differentially Expressed Genes (DEGs) Relevant to Prognosis of Ovarian Cancer by Use of Integrated Bioinformatics Analysis and Validation by Immunohistochemistry Assay.
    Zhang L; Sun L; Zhang B; Chen L
    Med Sci Monit; 2019 Dec; 25():9902-9912. PubMed ID: 31871312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioinformatic profiling identifies a platinum-resistant-related risk signature for ovarian cancer.
    Wu C; He L; Wei Q; Li Q; Jiang L; Zhao L; Wang C; Li J; Wei M
    Cancer Med; 2020 Feb; 9(3):1242-1253. PubMed ID: 31856408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EZH2 Loss Drives Resistance to Carboplatin and Paclitaxel in Serous Ovarian Cancers Expressing ATM.
    Naskou J; Beiter Y; van Rensburg R; Honisch E; Rudelius M; Schlensog M; Gottstein J; Walter L; Braicu EI; Sehouli J; Darb-Esfahani S; Staebler A; Hartkopf AD; Brucker S; Wallwiener D; Beyer I; Niederacher D; Fehm T; Templin MF; Neubauer H
    Mol Cancer Res; 2020 Feb; 18(2):278-286. PubMed ID: 31704732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of microarray-identified genes and microRNAs associated with drug resistance in ovarian cancer.
    Zou J; Yin F; Wang Q; Zhang W; Li L
    Int J Clin Exp Pathol; 2015; 8(6):6847-58. PubMed ID: 26261572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression profiling of epithelial ovarian cancer reveals key genes and pathways associated with chemotherapy resistance.
    Zhang M; Luo SC
    Genet Mol Res; 2016 Jan; 15(1):. PubMed ID: 26909918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of key molecular markers in epithelial ovarian cancer by integrated bioinformatics analysis.
    Qin W; Yuan Q; Liu Y; Zeng Y; Ke D; Dai X; Shuai Y; Hu J; Shi H
    Taiwan J Obstet Gynecol; 2021 Nov; 60(6):983-994. PubMed ID: 34794761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of chemo-response in serous ovarian cancer.
    Gonzalez Bosquet J; Newtson AM; Chung RK; Thiel KW; Ginader T; Goodheart MJ; Leslie KK; Smith BJ
    Mol Cancer; 2016 Oct; 15(1):66. PubMed ID: 27756408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene co-expression network reveals shared modules predictive of stage and grade in serous ovarian cancers.
    Sun Q; Zhao H; Zhang C; Hu T; Wu J; Lin X; Luo D; Wang C; Meng L; Xi L; Li K; Hu J; Ma D; Zhu T
    Oncotarget; 2017 Jun; 8(26):42983-42996. PubMed ID: 28562334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening and identification of key biomarkers in hepatocellular carcinoma: Evidence from bioinformatic analysis.
    Li L; Lei Q; Zhang S; Kong L; Qin B
    Oncol Rep; 2017 Nov; 38(5):2607-2618. PubMed ID: 28901457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-efficient Screening Method for Identification of Key Genes in Breast Cancer Through Microarray and Bioinformatics.
    Liu Z; Liang G; Tan L; Su AN; Jiang W; Gong C
    Anticancer Res; 2017 Aug; 37(8):4329-4335. PubMed ID: 28739725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of core serous epithelial ovarian cancer genes as potential prognostic markers and indicators of the underlying molecular mechanisms using an integrated bioinformatics analysis.
    Zhang YB; Jiang Y; Wang J; Ma J; Han S
    Oncol Lett; 2019 Nov; 18(5):5508-5522. PubMed ID: 31612059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Data Mining of Differentially Expressed Genes in Ovarian Epithelial Carcinoma: Implications in Precise Medicine.
    Zhao J; Gao H; He Y
    Curr Top Med Chem; 2021 Oct; 21(14):1285-1300. PubMed ID: 34238161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulation of NEK11 is associated with drug resistance in ovarian cancer.
    Liu X; Gao Y; Lu Y; Zhang J; Li L; Yin F
    Int J Oncol; 2014 Sep; 45(3):1266-74. PubMed ID: 24969318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis of transcriptome reveals let-7b as an unfavorable prognostic biomarker and predicts molecular and clinical subclasses in high-grade serous ovarian carcinoma.
    Tang Z; Ow GS; Thiery JP; Ivshina AV; Kuznetsov VA
    Int J Cancer; 2014 Jan; 134(2):306-18. PubMed ID: 23825028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Key Genes and Pathway for Ovarian Neoplasms Using the OVDM1 Cell Line Based on Bioinformatics Analysis.
    Yin S; Du J; Zhang J; Zhang X; Ma K
    Med Sci Monit; 2019 Jun; 25():4305-4313. PubMed ID: 31177266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inferences of carboplatin response-related signature by integrating multiomics data in ovarian serous cystadenocarcinoma.
    Yan JQ; Liu M; Ma YL; Le KD; Dong B; Li GH
    Exp Biol Med (Maywood); 2022 Jun; 247(11):910-920. PubMed ID: 35285286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.